RxDoctor Payments Data

Roman Berezovski, MD

Pain Medicine · Milwaukee, WINPI 1871569830

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,089 of the $3,969 with a category attached, or 77.8%. 20 manufacturers reported payments, led by Medtronic at 51.6% of the total. Reporting peaked in 2021 at $1,403 and has fallen 75.0% since, to $351 in 2023.

$3,969in general payments, 2019–2025

Across 175 payments — averaging $22.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Collegium Pharmaceutical, Inc.$409
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$390
  • Scilex Pharmaceuticals Inc.$309
  • Stryker$210
  • Biodelivery Sciences International, Inc.$176
  • plus $428 from 14 others

What the payments were for

  • Travel & lodging$85221%
  • Food & beverage$3,08978%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,969 in reported general payments places this provider in the 60th percentile of 82 pain medicine providers in Wisconsin.

See all pain medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$3,322
Medicare patients
21
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate21$8,622
Tramadol Hcl ErTramadol Hcl32$2,478
Gabapentin162$1,856
Naloxone Hcl29$1,838
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$1,299
Pregabalin64$1,094
Tramadol Hcl115$858
Methocarbamol56$813
Baclofen28$807
Tizanidine Hcl37$447
Acetaminophen-CodeineAcetaminophen With Codeine29$447
Diclofenac Sodium23$413
Duloxetine Hcl14$400
Morphine Sulfate ErMorphine Sulfate19$309
Methylprednisolone40$266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$409$8,62221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 82 pain medicine providers in Wisconsin.

Other pain medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →